Shopping Cart
Remove All
Your shopping cart is currently empty
Zovostotug
(Synonyms: OR-2805) Copy Product Info
🥰Excellent
Synonyms: OR-2805
Catalog No. T80720 Copy Product Info
🥰Excellent
Zovostotug is a human monoclonal antibody targeting human CD163 (Scavenger Receptor Cysteine-Rich Type 1 Protein M130). This product binds specifically to CD163, aiming to modulate the function of tumor-associated macrophages (TAMs) and improve the immunosuppressive tumor microenvironment. It serves as an important pharmacological tool for researching immunotherapy of solid tumors and macrophage phenotype switching.
Cas No. 2756228-84-7
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $223 | 4-6 weeks | 4-6 weeks | |
| 5 mg | $672 | 4-6 weeks | 4-6 weeks | |
| 10 mg | $1,070 | 4-6 weeks | 4-6 weeks | |
| 25 mg | $1,920 | 4-6 weeks | 4-6 weeks |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Zovostotug is a human monoclonal antibody targeting human CD163 (Scavenger Receptor Cysteine-Rich Type 1 Protein M130). This product binds specifically to CD163, aiming to modulate the function of tumor-associated macrophages (TAMs) and improve the immunosuppressive tumor microenvironment. It serves as an important pharmacological tool for researching immunotherapy of solid tumors and macrophage phenotype switching. |
| In vitro | In vitro assays demonstrate that Zovostotug exhibits high specificity for CD163-expressing myeloid cells and effectively binds to the surface of M2-type macrophages, enabling the precise identification and targeting of immunosuppressive cell populations [1]. |
| In vivo | In pharmacological studies using preclinical models, systemic administration of Zovostotug targets CD163-positive cell populations within the tumor microenvironment, leading to a reduction in tumor burden and a measurable shift in the intratumoral immune landscape [1]. |
| Synonyms | OR-2805 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | CD163 |
| Cas No. | 2756228-84-7 |
| Isotype | IgG1 |
| Storage | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Preview
Related Tags: Zovostotug chemical structure | Zovostotug in vivo | Zovostotug in vitro
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.